<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085029</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103137</org_study_id>
    <nct_id>NCT04085029</nct_id>
  </id_info>
  <brief_title>Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry</brief_title>
  <official_title>Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide a registry of participants in order to assess the
      acute adverse event rates following ablative radiotherapy for metastatic disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">September 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Occurrence of acute adverse events following radiotherapy</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Oligometastasis</condition>
  <condition>Metastatic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at any Duke University Health System Radiation Oncology treatment facility
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years of age

          -  Radiographic evidence of metastatic disease (may include oligoprogression,
             oligorecurrence or oligometastasis) at the time of study enrollment

          -  Planned to receive, currently receiving, or have completed hypofractionated image
             guided radiotherapy (ablative radiotherapy) to an extracranial site(s)

          -  Patient must sign study-specific informed consent

        Exclusion Criteria:

        • None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Salama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Mewshaw, MS NP</last_name>
    <phone>(919) 668 5211</phone>
    <email>jennifer.mewshaw@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Cancer Institute Cary</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebrina Wiggins, BSN MHA RN</last_name>
      <phone>919-576-8277</phone>
      <email>sebrina.wiggins@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mewshaw</last_name>
      <phone>919-668-5211</phone>
      <email>Jennifer.Mewshaw@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Women's Cancer Care Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebrina Wiggins, BSN MHA RN</last_name>
      <phone>919-576-8277</phone>
      <email>sebrina.wiggins@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Raleigh Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebrina Wiggins, BSN MHA RN</last_name>
      <phone>919-576-8277</phone>
      <email>sebrina.wiggins@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ablative radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

